Islet amyloidosis (IA) is the principal lesion in the endocrine pancreas of human beings with noninsulin-dependent diabetes mellitus (NIDDM) and in the similar forms of diabetes mellitus in domestic cats and macaques. As such, the delineation of the pathogenesis of this form of amyloidosis may be crucial to the understanding of the development and progression of NIDDM. Islet amyloid polypeptide (IAPP) is a recently discovered polypeptide that is the principal constituent of IA in human beings, cats, and macaques. IAPP is produced by the pancreatic @-cells and is co-packaged with insulin in the @-cell secretory vesicles. Immunohistochemical and physiologic evidence supports the notion that the &cells are heterogenous with respect to their relative contents of insulin and IAPP. Therefore, although IAPP is co-secreted with insulin in response to a variety of well-known insulin secretogogues, the molar ratio of these two proteins that is released from the islets may vary, depending upon the glucose concentration and prevailing metabolic milieu. IAPP is highly conserved among mammalian species and has about 45% homology to another neuropeptide, calcitonin gene-related peptide. IAPP is encoded by a single-copy gene located, in the human being, on chromosome 12. IAPP is expressed as a 93 (murinet89 (human)-amino acid prepropolypeptide that is processed enzymatically, resulting in the removal of amino-and carboxy-terminal propeptide segments. The 20-29 region of the IAPP molecule is most important in the ability of IAPP to form amyloid fibrils. The role of IAPP and IA in the pathogenesis of human NIDDM and similar forms of diabetes mellitus in cats and macaques may involve several possible mechanisms, including 1) direct physical/chemical damage to @-cells, resulting in necrosis and loss of functional islet tissue, 2) biologic activities of IAPP that oppose those of insulin or abnormally suppress insulin secretion, and 3) interference by IA deposits of passage of insulin out of &cells and/or entrance of glucose and other secretogogues into the islet. The roles of each of these possible mechanisms have yet to be demonstrated. In addition, the physiological significance of the apparent IAPP deficiency in both insulin-dependent diabetes mellitus and NIDDM is currently unknown.
Amyloid is not a single substance nor is amyloidosis a single disease. The various forms of amyloid are classified biochemically according to the protein precursors (the proteins from which the actual amyloid fibril is derived). To date, 15 different amyloid protein precursors have been identified. 51 Each of the various types of amyloid is associated with a particular disease or diseases (i.e., types of amyloidosis) with a pattern of deposition that generally may be classified as systemic or localized. 44 Systemic forms of amyloidosis typically present with amyloid deposits in many tissues. The most familiar example of systemic amyloidosis in animals (especially dogs, Abyssinian cats, cattle, and waterfowl) is the AA form (reactive or secondary amyloidosis), which commonly presents with amyloid deposits in the kidneys, liver, and spleen. 12,44, 55 The protein precursor of this form of amyloid is apoSAA, which is a plasma protein primarily found as part of the high-density lipoprotein fractions.* Localized forms of amyloidosis are limited to a single organ or sometimes are produced locally by tumors. Amyloid that occurs in the pancreatic islets in association with diabetes mellitus in cats, macaques, and human beings is a localized form of amyloidosis. This review is concerned with the pathogenesis of this form of amyloid, its precursor protein (islet amyloid polypeptide [IAPP]), and the role of islet amyloid (IA) and IAPP in the pathogenesis of human non-insulin-dependent diabetes mellitus (NIDDM) and the similar forms of diabetes mellitus in cats and macaques.
The two major forms of diabetes mellitus in human beings are categorized as insulin-dependent ([IDDM] type 1 or juvenile onset) or non-insulin dependent (type 2 or adult onset). The pathogenesis of IDDM involves Vet Pathol 304, 1993 the immune-mediated destruction of the pancreatic @-cells, resulting in their virtual e~t i n c t i o n .~~ Patients with IDDM have little or no detectable circulating insulin and become rapidly ketoacidotic of not treated with insulin. The pathogenesis of NIDDM is less well characterized but involves defects in both insulin secretion and insulin a c t i~n .~~J~~ Which of these defects, if either, is primary remains controversial. Risk factors include obesity, multiparity, and corticosteroid or growth hormone excess. 19. 25, 38, 108 Each of these risk factors is known to cause insulin resistance. It is therefore possible that insulin resistance represents the common pathway through which these risk factors induce expression of NIDDM in genetically predisposed subjects. Although neither the anatomic site nor the nature of the genetic component contributing to the onset of NIDDM has been determined, abnormal secretion by the pancreatic @-cells is probably involved. Lesions in the pancreatic islets of human beings with NIDDM are characterized by IA formation6~32~100J23J24J30 and the loss of up to 50% of the @-cells.105J09J24 Although still incompletely characterized, the most common form of diabetes mellitus in cats and macaques most closely resembles human NIDDM (rather than IDDM) both clinically and p a t h o l o g i~a l l y .~~.~~~~~~~~~,~~~ The most striking similarity between human NIDDM and diabetes of cats and macaques is the formation of portion of the @-cells.90J05J09J24 Because of the many similarities to human NIDDM (and for convenience of terminology), the common form of diabetes mellitus in cats and macaques (that incorporates IA formation and partial @-cell loss) will be referred to here as NIDDM.
An upsurge in interest in IA among diabetes researchers has been stimulated by the recent discovery that a previously undescribed protein, called islet amyloid p01ypeptidel~~J~~ (IAPP, also called diabetes associated peptideZ7 or amylin), has been identified as the principal constituent of the amyloid fibrils in these deposits. The implications of the discovery of what may be a new islet hormone and its likely relationship to the pathogenesis of diabetes mellitus in human beings and animals are far ranging and are to a large extent still in the early stages of investigation. This paper is a review of the experimental evidence accumulated so far concerning the biology of IAPP, the pathogenesis of IA formation, and the relationship of IA and IAPP to diabetes mellitus in human beings and animals. IA6,22,27,32,49,50,54,60,l00,101,l23-l25,I3c-l32, I37 and the loss of a
Characteristics of Islet Amyloid (IA)
The chemical nature of the "hyaline" material described by OpieIo0 in the pancreatic islets of diabetic patients went unknown for many years. Although the similarity of the islet hyaline material to amyloid was noted early on, the deposits were variously referred to as islet hyaline, fibrosis, or sclerosis until advances in histochemical techniques (Congo red staining and examination with polarized light microscopy) confirmed that the hyaline substance was a localized form of amy-10idosis.~~ Further confirmation of the amyloid nature of these deposits was obtained by subsequent electron microscopic evaluation of IA deposits from both human beings125 and These studies revealed nonbranching fibrils, 8-1 0 nm in diameter, that were identical to fibrils previously found associated with systemic amyloid deposits. IA in human beings and domestic cats was subsequently shown by histochemical and physiochemical techniques to be distinct from the common systemic forms of amyloid (i.e., reactive systemic [AA] or socalled primary [AL] amyloidosis). 126,127,138 Histochemically and spectrophotometrically, IA (unlike the systemic amyloids) has very low amounts of tyrosine and no tryptophan and does not react with antiserum to protein subunits derived from systemic forms of amyloid.28 Observation of these characteristics, which indicated a unique form of amyloid in the pancreatic islets of patients with diabetes, led to postulation that IA was derived from a local secretory product and that the determination of the chemical nature of this form of amyloidosis might provide an important clue to the pathogenesis of non-insulin-dependent diabetes mellitus.
Several lines of evidence initially suggested that IA was likely derived from a product of the @-cell. This notion was supported by the fact that amyloid deposits in the diabetic pancreas are limited to pancreatic islets. It was also known that individuals with insulin-dependent diabetes mellitus (who lack @-cells) never develop IA. Electron microscopic studies also supported the concept of a @-cell product as the precursor of IA because IA is often observed in close topographic association with islet @-cells. 1 2 5~1 2 8~1 3 8 The possibility that insulin was the major constituent of IA was supported by studies that showed that insulin was capable of forming amyloidlike fibrils in ~i t r o .~~J~~ Furthermore, IA deposits exhibited immunoreactivity to some antisera to insulin or insulin f r a g m e n t~.~~J~~ However, early studies showed that the amino acid composition of a low-molecular-weight material isolated from human islet amyloid differed from that of insulin or any of its subcomponents and suggested the possibility of origin from some other locally produced p~0 t e i n . l~~
Biology of Islet Amyloid Polypeptide (IAPP)

Structure of IAPP
In 1986-1987, human and feline islet amyloid and amyloid was isolated and purified from a human in- Table 1 . Comparison of amino acid sequences of IAPP* from multiple animal species with the sequence of human IAPP. Only amino acid residues different from the human sequence are indicated. Major regions of identity between species are present in the amino-and carboxy-terminal regions.
Species
Amino Acid Sequence 88, 89. t An N-terminal amino acid sequence representing positions 1-28 has been obtained from islet amyloid isolated from the cougar (Felis concolor). Parentheses represent residues not fully established.
sulinoma. Amino acid sequence analysis of these purified amyloid proteins revealed a previously unknown polypeptide, which was named IAPP (Table l) 
.131J32
Subsequently, another group of researchers identified the same polypeptide from human islet amyloid (IA) deposits and initially referred to the peptide as diabetes-associated ~e p t i d e~~ and later as a m~l i n .~~.~~ IAPP is comprised of 37 amino acid residues and has a theoretical molecular mass of 3,850 d a l t~n s .~~~. '~~ The peptide is amidated on its carboxy terminus and has a disulfide bond between cysteine residues at positions 2 and 7.11J06J11 The amino acid sequences of IAPP isolated from amyloid deposits in the human insulinoma and from IA deposits isolated from human pancreases are i d e n t i~a I .~~J~~J~~ The feline IAPP sequence differs from the human at four amino acid residues, a difference that is compatible with species ~a r i a t i o n .~J~~ Although its amino acid sequence is unique, IAPP has approximately 45% homology to the neuropeptide known as calcitonin gene-related peptide (CGRP).2.132 CGRP is also comprised of 37 amino acids, is carboxy amidated, and has a disulfide bond between residues 2 and 7. Extensive homology in the primary amino acid sequence of IAPP and CGRP is found in the amino-terminal regions (residues 1-1 9) and in the carboxyterminal regions (residues [30] [31] [32] [33] [34] . No homology is found in the region spanning residues 20-29. The similarities in structure between IAPP and CGRP and the extensively documented biologic activities of CGRP provide strong evidence that IAPP also has important biological effects.
The predominant molecular form of IAPP in the human pancreas is the intact molecule that includes all 37 amino acid residues.87 However, in human plasma the intact molecule accounts for only 3 1 Yo of IAPP immunoreactivity, suggesting that one or more circulating fragments of the molecule are In another study, a fragment of IAPP that included residues 17-37 was demonstrated to be a minor component of immunoreactive IAPP in human plasma. 86 Studies in rats have also shown that a carboxy-terminal peptide of IAPP spanning residues 19-37 is the major molecular form of the molecule in the pancreass Whether these IAPP fragments are biologically active is unknown, but a carboxy-terminal fragment of IAPP, which incorporates residues 24-37, binds to CGRP receptors with affinity nearly equal to that of the entire IAPP molecule.40 A fragment such as this, which retains its ability to bind to the receptor, may have biologic activity similar to the intact peptide or may act as a competitive inhibitor.
Tissue localization of IAPP
All evidence to date indicates that the pancreatic islets are the predominant site of IAPP production, which is consistent with the finding that the islets are the only known location in which IAPP polymerizes into amyloid. One exception to this is in the pancreatic neuroinsular complexes of the diabetic cat.94 These complexes contain P-cells that most likely account for the local production of IAPP, which then can polymerize into amyloid. Within the pancreatic islets of all species thus far studied, including human beings, cats, dogs, Celebese macaques (Macaca spp.), mice, rats, guinea pigs, hamsters, and degus (Octodon degus), IAPP immunoreactivity is predominantly if not exclusively located in the pancreatic @-cells ( Fig. 1 a, c) .57,58,72J32 Nevertheless, IAPP expression is not absolutely restricted to @-cells. For example, in cultured neonatal rat islet cells, IAPP is expressed in cells that also pro- Note also that remaining islet @-cells lack IAPP immunoreactivity. Bar = 50 pm. duce glucagon or ~omatostatin.~~ Likewise, in murine transformed islet cell cultures, the expression of IAPP is not invariably linked to insulin. In fact, the expression of insulin and IAPP in unstable heterogeneous NHI-6F clones is completely uncoupled. In some species (especially human beings), although insulin immunoreactivity in ,&cells appears to be relatively constant from cell to cell, the amount of IAPP immunoreactivity appears to be variable ( Fig. la) (T. D. O'Brien, P. C. Butler, K. H. Johnson, personal observations). Therefore, there probably are distinct subpopulations of @-cells that secrete different proportions of insulin and IAPP.
Ultrastructurally, IAPP immunoreactivity in normal cat islets resides predominantly in the @-cell secretory vesicle, principally in the outer lucent zone. 57 In comparison, IAPP immunoreactivity in human islets occurs principally in the dense core of the P-cell secretory vesicles. 72 The significance of this apparent species difference is unknown. Some IAPP immunoreactivity may also be found in lysosomes or lipofuscin bodies within which may indicate that IAPP is degraded in lysosomes and so may accumulate in these structures under pathologic conditions. In situ hybridization studies of the rat pancreatic islets have indicated that IAPP mRNA is predominantly located in the p-cells. 68 The localization of IAPP immunoreactivity in the &cell secretory vesicles provided the first evidence that IAPP is co-secreted with insulin. Subsequent studies assessing in vivo and in vitro insulin and IAPP secretion have confirmed this hypothesis.
Quantification of IAPP mRNA by Northern blotting shows it to be most abundant in the pancreatic islets,37 which is consistent with the results of immunohistochemical studies. Some IAPP mRNA is found in the stomach and, to a lesser degree, in the dorsal root ganglion and lung of the rat. Scattered endocrine cells with IAPP immunoreactivity reportedly occur in the mucosa of the stomach, duodenum, and recturn.ll8 These gastrointestinal endocrine cells apparently do not contain other identifiable hormones.Il8 There are no reports describing a cellular location for IAPP in either the dorsal root ganglion or lung.
IAPP gene structure and expression
Human IAPP is encoded by a single-copy gene that is located on the short arm of chromosome 12.17,21,24*82,88
The chromosomal location has been reported variously as 12~12-13'~@ and/or 12q13-14.21*24 In comparison, both of the human CGRP genes are located on chromosome 1 1, which is considered an evolutionary homologue of chromosome 12.16 This location is consistent with the possibility that the two genes are descended from a common ancestral gene. The rat and human IAPP genes are similar and are both comprised of three exons and two introns.21, 81, 82, 88, 121 The three exons of the human IAPP gene are arranged as follows: exon 1 is comprised of 104 base pairs and encodes most ofthe 5' untranslated region; exon 2 is comprised of 95 base pairs and encodes 15 nucleotides of the 5' untranslated region, the signal peptide, and five residues of the amino-terminal propeptide; and exon 3 is comprised of 1,246 base pairs and encodes the remainder of the amino-terminal propeptide, IAPP, the carboxy-terminal propeptide, and the 3' untranslated region of the mRNA. In the human 3' flanking region, three polyadenylation sites have been identified, all of which appear to be used, as judged from structural analysis of complementary CDNA clones.21. 82 The presence of three polyadenylated IAPP mRNAs with estimated sizes of 1.2, 1.8, and 2.1 kilobases (kb) in human insulinoma mRNA supports this hypothesis.21
Regulatory elements for the IAPP gene have been identified in the 5' upstream flanking region within about 1,500 kb of exon 1 .21J21 Studies of the structure of the 5' upstream sequences of the human and rat IAPP genes reveal similarities and differences in the regulatory elements of these species. Specifically, the upstream sequence of the human gene contains a TATA box and a sequence similar to the rat insulin enhancer.I2l In comparison, the upstream region of the rat gene contains a TATA box, a CCAAT sequence, and a GT element.12' These differences suggest that the IAPP gene may be regulated differently in these species. In an experiment employing CAT gene constructs controlled by 1,500 kb of IAPP 5' flanking sequence, the CAT gene was expressed in hamster insulinoma but not in Chinese hamster ovary (CHO) cells, indicating cell-specific expression of IAPP.2' Another study found that deletion of a region from 189 to 800 base pairs upstream from exon 1 of the human IAPP gene will increase gene expression five-to six-fold, which suggests that this region has a gene suppressor effect. 80 Further studies concerning the expression of the IAPP gene in vivo and comparative aspects of the structure of the regulatory sequences in other species, especially those that develop IA and non-insulin-dependent diabetes mellitus (NIDDM), may help to clarify the role of regulation of IAPP gene expression in the pathogenesis of IA and NIDDM.
Human IAPP is expressed as an 89-amino acid prepropolypeptide with a 22-amino acid N-terminal signal peptide for transport through the endoplasmic reticulum.llJ1l Rat IAPP is similar but is expressed as a 93-amino acid prepropolypeptide with a 23-amino acid signal peptide and 3 additional amino acids in the amino-terminal propeptide. 68 The propeptide has two short flanking peptides that are removed by proteolytic cleavage at pairs of basic amino acid residues, similar Pancreas; normal (fed) rat. Insulin and IAPP secretion from pancreases perfused in vitro. Perfusion buffer contained 2.75 mM glucose from 0 to 20 minutes and 16.7 mM glucose from 20 to 50 minutes of perfusion. Note that the pattern of secretion of these peptides in response to glucose is virtually identical and compatible with their co-release from the @-cell secretory vesicles.
to the situation for other polypeptide hormones. Comparisons of IAPP structure based upon cDNA predictions or amino acid sequence analysis among several mammalian species shows close homology among all species in the amino-(residues 1-19) and carboxyterminal (residues 30-37) regions. Less homology is generally present in the portion of the molecule spanning residues 20-29, especially between rodents and other mammalian species. This region of the molecule appears to be important in the formation of amyloid fibrils and will be discussed in more detail. Little homology is found for the propeptides among species, which suggests that these molecules probably do not have biologic activity.
Secretion of IAPP
As the morphologic studies predicted, IAPP and insulin secretion in vivo or in vitro from isolated islets or pancreas are qualitatively and temporally similar, which is consistent with the concept that they are coare found in increased concentrations in the culture medium from isolated pancreatic islets cultured in concentrations of glucose and arginine that stimulate insulin ~e c r e t i o n .~~,~~ Similarly, in the perfused rat pancreas IAPP is secreted roughly in parallel with insulin following stimulation with glucose, arginine, P-hydroxybutyrate, and IAPP has a secretion curve that is qualitatively similar to that of insulin under these conditions and that includes an acute phase spike of secretion during the first 5 minutes following stimulation and a second phase secretion that begins by 5 minutes following stimulation and extends for at least 30 minutes when glucose stimulation is secreted (Fig. 2). 18,35,46,52,53,63,64,76,97,98 ,1 I2 Both peptides continued. 97 In human beings, IAPP concentrations in peripheral blood increase following a meal or after intravenous glucose tim mu la ti on.^'^^^^^^^^^^^^^^^^^ Fasting plasma levels are between 2 and 12 pM, and peak values in plasma following an oral glucose load are about two-to threefold higher. 18,46,76~1 I2
Although insulin and IAPP are co-secreted, expression of these two proteins is, at least to some extent, independently regulated. Therefore, the relative amounts of IAPP and insulin released from the pancreas are variable and depend upon the prevailing metabolic milieu. For example, fasting reduces the ratio of IAPP: insulin secreted in response to glucose (16.7 mM) in the isolated perfused rat pancreas and reduces the amount of IAPP demonstrable by immunohistochemical techniques as compared with that in fed cont r o l~.~~ In contrast, pancreases from rats pretreated with dexamethasone or from rats made hyperglycemic by intraperitoneal injections of glucose have a proportionately greater increase in IAPP secretion versus insulin secretion in response to 16.7 mM glucose, and the relative amount of IAPP immunoreactivity is greater in the rats treated with dexamethasone or glucose as compared with that in fed Studies of pancreatic IAPP mRNA levels agree with these secretory studies and show a larger increase in IAPP mRNA than in insulin mRNA in rats treated with dexamethasone. l 4
The IAPP: insulin ratio also changes over the time course of the secretory response,y7 suggesting that there may be different pools of insulin/IAPP secretory vesicles within the P-cells that are recruited at different stages of secretion. However, another more attractive hypothesis proposes that there may be subpopulations of &cells that contain different proportions of IAPP and insulin and that are recruited to secrete at different glucose concentration^.^^ This notion is supported by studies that have shown that the increased insulin secretion seen with increasing glucose concentrations is due to increased numbers of P-cells recruited to secrete rather than increased secretion from individual p-cells.66J13 The subpopulation hypothesis is also consistent with the observation that there is heterogeneity with respect to the immunoreactive IAPP content of P-cells and suggests that cells with a relatively greater ratio of IAPP : insulin tend to secrete at lower glucose concentrations than those with lower IAPP : insulin ratios. The functional importance of this relationship is yet to be clarified but may be related to the necessity for more precise regulation of insulin effects at low glucose concentrations.
IAPP receptor
The close structural similarity between IAPP and CGRP suggests that they may compete for receptors and therefore share at least some biologic effects. Several studies have now shown that IAPP can indeed displa~el~~I-CGRP from receptors in several tissues. In one study, brain, skeletal muscle, and liver were all shown to have two classes of receptors (high and low affinity) that bound both CGRP and IAPP. 40 In each of these tissues, IAPP was able to displace 1251-CGRPa from a high-affinity receptor but with an IC,, about 1,000-fold greater than that of CGRPa. At the lowaffinity receptor, the IC,,s of IAPP and CGRP were much closer in value, especially in the liver, where they were 20 nM (CGRP) and 35 nM (IAPP). The IC,, for IAPP at the high-affinity receptor was also lowest in the liver (2 nM), whereas values were 7 nM in muscle and 13 nM in brain. Thus IAPP is able to compete with CGRP for receptors in these tissues but requires much greater concentrations of peptide than does CGRP to achieve a given degree of receptor occupancy. Even for the high-affinity receptors that had the lowest IC,, values, the IC,, concentrations are 100-1,000-fold greater than have as yet been shown to occur in the peripheral c i r~u l a t i o n .~~,~~,~~J~~ Therefore, it is still questionable as to whether IAPP has much biologic activity via CGRP receptors.
IAPP, like many biologically active polypeptides, is amidated on its carboxy-terminal amino acid.ll' At present, some disagreement exists as to the necessity of this amide in the ability of IAPP to compete with CGRP for receptor binding sites in tissues and to produce biologic effect^.^,,^^ In one study, rat or human IAPP amide dose-dependently displaced 1251-CGRPa from hepatic membrane preparations, whereas nonamidated human IAPP had no effect. 79 The authors also showed that the amidated peptides, but not the nonamidated IAPP, evoked a dose-dependent activation of adenylate cyclase in liver membranes. However, another study found that the IC,, of human amidated IAPP for displacement of rat 1251-CGRPa from rat skeletal muscle membranes was significantly less than that of nonamidated human IAPP at a high-affinity receptor, whereas there was no significant difference between the two peptides at the low-affinity receptor. 40 In addition, the IC,, of a nonamidated synthetic carboxy-terminal fragment of cat IAPP incorporating residues 24-37 was not significantly different from that of the entire amidated form of IAPP at either receptor in skeletal muscle.4o The receptor binding activity of the carboxy-terminal peptide in that study suggests that this portion of the IAPP molecule is important in receptor binding to both the high-and lowaffinity receptors in skeletal muscle. Nonamidated forms of IAPP may be able to bind to receptors but may not evoke a biologic effect. The potential of this carboxy-terminal fragment as a competitive inhibitor of IAPP actions needs further investigation, especially because CGRP,,, can act as a competitive inhibitor of both CGRP and IAPP receptor binding. 79 In addition, CGRP,-,, can antagonize the hemodynamic effects of IAPP in the rat. 41 Attempts to demonstrate a specific IAPP receptor in tissues or membrane preparations using radiolabeled IAPP have so far failed.40 This failure may be due to the method of iodination that has been employed to radiolabel IAPP. The most commonly used method (chloramine-T or related procedures) labels the peptides through tyrosine residues. In IAPP, the only tyrosine is residue 37. Because this portion of the molecule appears to be important in binding to CGRP receptors, the iodine may be changing the conformation of this portion of the molecule enough to interfere with binding of the ligand to the receptor. Further studies are needed with IAPP tracers labeled at another site to resolve this problem and to determine whether a separate class of IAPP receptors exists that will have biologic activity at concentrations normally found in blood.
Biologic actions of IAPP
Several studies have addressed the possibility that IAPP inhibits insulin secretion. This prospect is plausible because similar effects have been reported for CGRP1J04 and because IAPP can compete with CGRP for receptor^.^^.^^ Although the data regarding these effects are conflicting, many experiments using isolated perfused rat pancreas or isolated rat islets have generally shown no effect by either human or rat IAPP on glucose-stimulated insulin secretion in concentrations up to 100 nM.334, 96, 99 In vivo experiments have also shown no effects. L5,42~103 However, experiments using rat IAPP in concentrations above 750 pM have shown an inhibitory effect on glucose-stimulated insulin secretion from isolated rat islets or perfused rat pan-~r e a s .~~. "~ Although the effective concentrations of IAPP that were used in these experiments are over a million-fold higher than those measured in plasma,18,46,76J l 2 IAPP may achieve such concentrations in the local environment of the pancreatic islet. Because normal insulin secretion occurs in a pulsatile manner, the IAPP that is co-secreted with insulin may act as the "brake" that generates these insulin pulses. Further studies are needed to confirm or refute this possibility.
The fact that IAPP is a circulating peptide has prompted studies of its potential biologic effects on tissues such as skeletal muscle, liver, and adipose tissue. In skeletal muscle, IAPP inhibits basal and insulin-stimulated glycogen ~y n t h e s i s ,~~.~~.~~ causes a reduction in insulin-stimulated uptake of 2-de-0xyg1ucose~~J~~ and 3-0-methyl glucose,141 and results in reduced glycogen content and increased glucose-6phosphate concentrations in skeletal muscle. 39 No ef-Vet Pathol 30:4, 1993 fects were detected in adipose tissue. Some hyperinsulinemic euglycemic clamp studies have demonstrated that IAPP can impair insulin suppression of hepatic glucose output and reduce insulin-stimulated peripheral glucose ~p t a k e ;~~,~~, ' however, other studies have failed to find these e f f e~t s .~~J l~
The significance of the reported effects on hepatic and skeletal muscle metabolism may be questionable because of the concentrations of IAPP needed to produce the above effects both in vitro and in vivo. For example, in the in vitro experiments the effects are generally not seen unless concentrations of peptide are in the nanomolar or higher range. Similarly, the concentrations of infused IAPP needed to produce effects in the hyperinsulinemic euglycemic clamp studies produce plasma concentrations much higher than have been reported in normal or diabetic subjects. The fact that the concentrations needed to obtain any of these biologic effects are near the range of the IC,, value for IAPP displacing 1251-CGRP from receptors suggests that these effects might be mediated by IAPP binding to CGRP receptor^.^^ This possibility is also supported by the fact that CGRP has effects similar to IAPP in virtually all of these experimental systems. The difficulties in interpreting these data are further complicated by technical difficulties in performing radioimmunoassays for IAPP in plasma or serum, leading to differences in the reported normal (and abnormal) range of concentrations for IAPP. The purity and biologic potency of some synthetic IAPP preparations has been questioned and could also contribute to the confusion regarding the concentrations at which IAPP is biologically active. Therefore, until biologic effects of IAPP can be shown to occur at concentrations corresponding to those measured in blood, the possibility that IAPP plays an important role in the pathogenesis of peripheral insulin resistance and hepatic glucose metabolism remains an unproven but still intriguing hypothesis.
IAPP, like CGRP, is a potent vasodilator and causes systemic hypotension and tachycardia when injected i n t r a v e n~u s l y .~~,~~ IAPP is about 100 times less effective on a molar basis than is CGRP in these studies. Intradermal injection of IAPP results in vasodilation without edema but, in combination with bradykinin, will potentiate edema f0rmati0n.l~ IAPP also has produced marked hypocalcemia in rats and rabbits when given i n t r a v e n o~s l y .~~,~~J~~ These effects were due to a marked reduction of bone resorption by osteoclasts. These hypocalcemic effects of IAPP were more potent than those of CGRP but about 3 0 4 0 times less potent than calcitonin. Recent studies have shown that IAPP is produced and secreted by an osteoblast cell line, indicating that IAPP may be a potential paracrine regulator of osteoclast function. 43 These findings suggest that IAPP may play a role in the pathogenesis of such conditions as Paget's disease and o~teomalacia.~~ Anorexia occurs when IAPP is injected into the hypothalamus of rats.20 Injection of 2 pg of IAPP into rats significantly reduces food intake for 8 hours. This effect was more potent than that of CGRP in the same experimental system. IAPP was also demonstrated in rat hypothalamus at concentrations much higher than those in other areas of brain.20 These findings suggest a potential role of IAPP in food ingestive behavior.
Pathogenesis of Islet Amyloidosis
Islet amyloid (IA) occurs in only a limited number of species (e.g., human beings, macaques, and cats) ( Fig. lc, d, f) , usually in conjunction with diabetic syndromes associated with aging, and does not (with the exception of the degu) occur in rodent^.,^^^^ This observation prompted the comparison of islet amyloid polypeptide (IAPP) structures in these species to determine whether primary or secondary structural differences within or between species might account for this situation.
All of the evidence gathered so far indicates that a mutation in the IAPP coding region is an unlikely explanation for the development of IA. Amino acid sequence analysis of IAPP isolated from amyloid deposits reveals the same amino acid sequence as IAPP isolated from normal pancreas.4,27*86J31J32 Furthermore, both cDNA and genomic DNA sequences of IAPP from normal human beings and cats predict IAPP peptides identical to those isolated from IA deposits in human beings and cats with diabetes rnellit~s.~JlJ I 1 These studies do not preclude the possibility that defects that predispose an individual to the development of IA might be present in the regulatory regions of the IAPP gene.
Comparisons among the IAPP sequences of several different mammalian species reveal highly conserved regions in the amino-terminal (residues 1-19) and carboxy-terminal (residues 30-37) regions of the molecules but notable variations in the sequence in the region spanning residues 20-29 (Table l) .loJL Secondary structural predictions of this region of the human IAPP molecule indicate a propensity to form a beta pleated sheet configuration' I (necessary for amyloid fibril formation). Experiments with synthetic peptides corresponding to the amino acid sequence of human and cat IAPP in the 20-29 region show that these peptides readily form congophilic fibrils that are ultrastructurally identical to amyloid fibrils seen in pancreatic islets. IZ9 Synthetic peptides corresponding to the 20-29 region of rodent IAPPs do not form amyloid fibrils.129 The 25-28 region of human and cat IAPP is identical in structure (i.e., Ala-Ile-Leu-Ser [AILS]) and appears to be the most important amyloidogenic se-quence common to human and cat IAPP. Substitutions of single amino acids in the 25-28 region of synthetic human IAPP 20-29 significantly reduce or eliminate the amyloidogenicity of these peptides.Iz9
The degu (which is the only rodent species known to form IA deposit^^^,^^) has an IAPP sequence similar to that of other rodents89 and therefore would not be predicted to form IA. This apparent conflict was resolved by the demonstration that degu IA is not derived from IAPP, as it is in all other species thus far studied, but rather is derived from i n~u l i n .~~.~~ Insulin has the ability to form amyloid fibrils in vitro126 and at sites of repeated insulin i n j e~t i o n .~' , "~ Simply having an IAPP sequence capable of forming amyloid fibrils is obviously not sufficient for IA to develop, or consequently, the prevalence of IA in human beings, cats, and macaques would be 100%. Canine IAPP possesses the amyloidogenic amino acid sequence (AILS), but dogs do not develop IA.62 However, IAPP-derived amyloid deposits do occur in canine pancreatic endocrine tumors95 (consistent with the theory that the AILS sequence is important in the ability of IAPP to form IA). Therefore, abnormalities in IAPP synthesis, processing, secretion, or degradation by &cells also must play a role in the pathogenesis of IA. This concept is supported by the fact that the @-cells of cats with impaired glucose tolerance have increased IAPP immunoreactivity (as compared with normal controls),59 which suggests that there is an imbalance between IAPP production and secretion/degradation in these cats. The importance in the pathogenesis of IA of the increase in IAPP content in cats with impaired glucose tolerance is supported by the observation that these cats also have an increased incidence of IAPP-derived IA.59 Further studies are required to delineate where in the IAPP production, secretion, or degradation pathways the abnormalities associated with IA formation occur.
Another factor concerning the formation of islet amyloid is the location of the initial amyloid deposits. Are the deposits initially intracellular or extracellular? Within affected pancreatic islets, the vast bulk of the amyloid is extracellular; however, intracellular amyloid has been observed in unidentified islet cells in nondiabetic cats with minimal extracellular IA138 and in islet cells of diabetic cats (Fig. 3) . 57 Often these intracellular amyloid deposits occur in membrane-bound structures of unknown derivation. Amyloid deposits within these structures show a pattern of maturation that suggests that these deposits result from intracellular production rather than from phagocytosis of extracellular amyloid. 138 Amyloid deposits that occur in both h~m a n~~. l 19~132 and ~a n i n e~~.~~ pancreatic endocrine tumors are, like IA, derived from IAPP. Intracellular amyloid deposits have been reported in these tumors, and these reports may lend some support to the notion that the formation of amyloid is initially intracellular. A similar pattern of intracellular amyloid formation has been noted in various pituitary tumors (amyloid derived from growth hormone or prolactin).79J10 In pituitary tumors, amyloid has been found in membrane-bound structures suspected to be endoplasmic reticu1um.l l o Intracellular amyloid formation might occur due to unregulated production of IAPP (endocrine tumors), defective intracellular processing and transport of IAPP, defective secretion of IAPP (possibly in non-insulin-dependent diabetes mellitus), defective degradation of IAPP, or combinations of these defects.
Role of Islet Amyloid and Islet Amyloid Polypeptide in the Pathogenesis of Non-insulin-dependent Diabetes Mellitus
The pathogenesis of human non-insulin-dependent diabetes mellitus (NIDDM) has not been determined but clearly involves both genetic and environmental factors. Fewer studies concerning the pathogenesis of NIDDM in cats and macaques have been done, but Vet Pathol 304. 1993 the known similarities in clinical and pathologic features suggest that they share similar etiopathogenic features. Human NIDDM is characterized by both insulin resistance30 and a progressive defect in insulin secretion.Io7 Which of these features is the primary defect has been the center of intense debate among diabetes researchers for decades. It has been argued that because insulin resistance has been identified prior to impaired insulin secretion in patients at risk of development of NIDDM, insulin resistance must be the primary and presumably the genetic defect.34 However, these studies have not allowed for the fact that more sophisticated techniques were employed to assess insulin action than insulin secretion, so that early defects in insulin secretion may not have been detected. Furthermore, if insulin resistance were truly the primary determinant of NIDDM, all subjects with prolonged insulin resistance should develop NIDDM. In fact, the majority of human patients with long-standing insulin resistance do not develop NIDDM. Thus, about 20% of patients with massive obesity,36 acromegaly,135 or Cushing's syndrome122 develop NIDDM, whereas about 80% of these patients compensate adequately with islet hyperplasia and increased insulin secretion. Therefore, a genetic defect in insulin secretion probably is required for susceptibility to NIDDM. The classic studies of Yalow and B e r~o n~~~ first showed that the insulin response to glucose is impaired in NIDDM. This defect is even more apparent when the plasma glucose concentration is matched in diabetic and nondiabetic subjects.Io2 But the question still remains: What is the primary islet defect?
Concerning the lesions in the pancreatic islets, many studies have confirmed that human beings, domestic cats, and macaques with NIDDM have both an increased frequency of islets that contain islet amyloid (IA) and larger amounts of IA deposited per islet than do age-matched C O~~~~~S .~,~~,~~,~~J~~J~~J~~ Thus, the association between the occurrence of IA and NIDDM is well established. A second morphologic feature of NIDDM is the loss of a portion of the @-cell mass, which may be as severe as 50%.105J09,124 Therefore, any theories concerning the pathogenesis of NIDDM must take into account the formation of IA and the concurrent loss of P-cells.
One hypothesis can be derived from several lines of evidence. Experimental support for the idea that the primary lesion of NIDDM involves defective secretion by P-cells leads to the hypothesis that under conditions of chronic stimulation (due to insulin resistance) an imbalance between synthesis and secretion may occur in the P-cells. In this situation, the maximal normal rate of islet amyloid polypeptide (IAPP) synthesis exceeds the secretory rate (which is defective). The prediction in this scenario is that the first cells to be affected would be the P-cells that respond to the lowest concentrations of glucose (because these cells are stimulated to secrete a greater portion of the time). Evidence also suggests that the P-cells with the lowest glucose threshold have the highest ratio of IAPP : in-~u l i n .~~ Each of these conditions (maximal IAPP synthesis, defective secretion, and a high relative content of IAPP) might predispose these P-cells to develop intracellular amyloid deposits by increasing the intracellular IAPP content. Formation of intracellular amyloid could then damage the affected P-cells and lead eventually to necrosis and release of the amyloid into the extracellular space. This hypothesis, although highly speculative, is compelling in that it is consistent with the epidemiology of NIDDM in explaining why only some individuals with insulin resistance develop NIDDM while it provides an explanation for the formation of IA and the loss of some (but not all) @-cells in NIDDM. Furthermore, the preferential loss of @-cells that respond to lower glucose concentrations is compatible with the progressive increase in fasting blood glucose concentrations seen in NIDDM. Experimental data are needed to confirm or refute this hypothesis.
Some of the other proposed or potential roles for IA and IAPP in the pathogenesis of NIDDM include 1) increased IAPP secretion, which would lead to inhibition of insulin secretion and/or exert effects on skeletal muscle and liver that oppose those of insulin, 2) physical interference by IA deposits in transport of glucose into P-cells and insulin from the P-cells into the islet capillaries, and 3) direct physical/chemical damage to P-cells by the formation of extracellular IA deposits.
Elevated plasma IAPP concentrations in obese hurnans1l2 and increased IAPP immunoreactivity in cats with impaired glucose tolerance59 suggest that the counterinsulin effects of IAPP might play a role in the pathogenesis of impaired insulin secretion and peripheral insulin resistance in developing NIDDM. However, results of studies of human beings with NIDDM do not support this hypothesis but rather indicate that plasma concentrations of IAPP are normal or lower than n~r m a l .~* ,~~J I~ This finding is also in agreement with immunohistochemical data that show markedly reduced or absent IAPP immunoreactivity in islets of cats59 and human beings134 with NIDDM. These observations indicate that NIDDM is a condition of IAPP deficiency rather than systemic IAPP excess. The physiologic significance of this deficiency is at present unknown. However, therapeutic regimens incorporating mixtures of insulin and IAPP might, by virtue of the counterinsulin effects of IAPP (especially on liver), enable more precise and physiologic management of blood glucose in both insulin-dependent diabetes mellitus and NIDDM. In this scenario, IAPP might serve to blunt the initial hypoglycemic effects of an insulin dose while not interfering with the later peak effect. The potential relationship between IAPP deficiency and the development of secondary complications of diabetes mellitus (e.g., renal disease, retinal damage, polyneuropathy, and microvascular and macrovascular disease) is also unexplored.
The possibility that the deposition of IAPP as IA may in itself impair the ability of the islet to function normally has been considered for many years. IA deposition is often extensive, both in the number of islets involved and in the amount of IA deposited, in the islets of human patients with NIDDM and of diabetic crease in IA deposition is also associated with loss of functional islet tissue and therefore is also likely associated with additional loss of islet function (especially regarding insulin ~e c r e t i o n ) .~~J~~ IA may be seen adjacent to @-cells exhibiting damage to the plasma membrane and therefore may be associated with direct physical/chemical damage to the cell membranes. 125 If the theory of intracellular amyloid formation is correct, this mechanism (ie., extracellular amyloid damage to islet cells) might also contribute to the progression of the islet damage. No direct experimental evidence is available regarding the possibility that IA interferes with the passage of insulin out of @-cells or with the passage of substances from the blood stream to the @-cells. More experimental evidence is needed to assess these possibilities. 
